Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 81.28
TRGT's Cash to Debt is ranked higher than
73% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. TRGT: 81.28 )
TRGT' s 10-Year Cash to Debt Range
Min: 11.33   Max: No Debt
Current: 81.28

Equity to Asset 0.92
TRGT's Equity to Asset is ranked higher than
94% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. TRGT: 0.92 )
TRGT' s 10-Year Equity to Asset Range
Min: -5.8   Max: 0.93
Current: 0.92

-5.8
0.93
F-Score: 2
Z-Score: 4.59
M-Score: -3.91
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -1301.07
TRGT's Operating margin (%) is ranked higher than
53% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. TRGT: -1301.07 )
TRGT' s 10-Year Operating margin (%) Range
Min: -2537.37   Max: 15.3
Current: -1301.07

-2537.37
15.3
Net-margin (%) -1286.99
TRGT's Net-margin (%) is ranked higher than
53% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. TRGT: -1286.99 )
TRGT' s 10-Year Net-margin (%) Range
Min: -2456.95   Max: 12.72
Current: -1286.99

-2456.95
12.72
ROE (%) -34.70
TRGT's ROE (%) is ranked higher than
66% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. TRGT: -34.70 )
TRGT' s 10-Year ROE (%) Range
Min: -57.11   Max: 11.87
Current: -34.7

-57.11
11.87
ROA (%) -32.02
TRGT's ROA (%) is ranked higher than
66% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. TRGT: -32.02 )
TRGT' s 10-Year ROA (%) Range
Min: -103.54   Max: 4.15
Current: -32.02

-103.54
4.15
ROC (Joel Greenblatt) (%) -6923.17
TRGT's ROC (Joel Greenblatt) (%) is ranked higher than
52% of the 868 Companies
in the Global Biotechnology industry.

( Industry Median: -189.80 vs. TRGT: -6923.17 )
TRGT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -6923.17   Max: 215.99
Current: -6923.17

-6923.17
215.99
Revenue Growth (%) -66.20
TRGT's Revenue Growth (%) is ranked higher than
54% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -0.40 vs. TRGT: -66.20 )
TRGT' s 10-Year Revenue Growth (%) Range
Min: -67.4   Max: 68.8
Current: -66.2

-67.4
68.8
» TRGT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

TRGT Guru Trades in Q1 2013

Jim Simons 328,879 sh (-1.69%)
» More
Q2 2013

TRGT Guru Trades in Q2 2013

Chuck Royce 40,000 sh (New)
Jim Simons 266,879 sh (-18.85%)
» More
Q3 2013

TRGT Guru Trades in Q3 2013

Jim Simons 314,397 sh (+17.81%)
Chuck Royce 40,000 sh (unchged)
» More
Q4 2013

TRGT Guru Trades in Q4 2013

Chuck Royce 40,000 sh (unchged)
Jim Simons 143,059 sh (-54.5%)
» More
» Details

Insider Trades

Latest Guru Trades with TRGT

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2012-12-31 Sold Out 0.01%$3.99 - $4.78 $ 4.27-4%0
Jean-Marie Eveillard 2012-09-30 Reduce -58.86%0.01%$4.22 - $5.12 $ 4.27-6%600000
Seth Klarman 2012-03-31 Sold Out 1%$5.03 - $7.5 $ 4.27-28%0
Jean-Marie Eveillard 2012-03-31 Add 584.3%0.02%$5.03 - $7.5 $ 4.27-28%1368600
Seth Klarman 2011-12-31 New Buy1%$4.99 - $19.25 $ 4.27-63%6000000
Jean-Marie Eveillard 2011-12-31 New Buy$4.99 - $19.25 $ 4.27-63%200000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.10
TRGT's P/B is ranked higher than
97% of the 787 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. TRGT: 1.10 )
TRGT' s 10-Year P/B Range
Min: 0.7   Max: 12.59
Current: 1.1

0.7
12.59
EV-to-EBIT 22.70
TRGT's EV-to-EBIT is ranked higher than
53% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. TRGT: 22.70 )
TRGT' s 10-Year EV-to-EBIT Range
Min: 21.8   Max: 48.2
Current: 22.7

21.8
48.2

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.80
TRGT's Price/Net Cash is ranked higher than
95% of the 476 Companies
in the Global Biotechnology industry.

( Industry Median: 9.10 vs. TRGT: 1.80 )
TRGT' s 10-Year Price/Net Cash Range
Min: 1.32   Max: 17.79
Current: 1.8

1.32
17.79
Price/Net Current Asset Value 1.80
TRGT's Price/Net Current Asset Value is ranked higher than
95% of the 520 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. TRGT: 1.80 )
TRGT' s 10-Year Price/Net Current Asset Value Range
Min: 1.31   Max: 48.6
Current: 1.8

1.31
48.6
Price/Tangible Book 1.10
TRGT's Price/Tangible Book is ranked higher than
97% of the 727 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. TRGT: 1.10 )
TRGT' s 10-Year Price/Tangible Book Range
Min: 0.84   Max: 8.57
Current: 1.1

0.84
8.57
Price/Median PS Value 0.80
TRGT's Price/Median PS Value is ranked higher than
83% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. TRGT: 0.80 )
TRGT' s 10-Year Price/Median PS Value Range
Min: 0.37   Max: 4.52
Current: 0.8

0.37
4.52
Earnings Yield (Greenblatt) 4.40
TRGT's Earnings Yield (Greenblatt) is ranked higher than
63% of the 379 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. TRGT: 4.40 )
TRGT' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.1   Max: 4.6
Current: 4.4

2.1
4.6
Forward Rate of Return (Yacktman) -7.96
TRGT's Forward Rate of Return (Yacktman) is ranked higher than
76% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. TRGT: -7.96 )
TRGT' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -54.9   Max: -7.5
Current: -7.96

-54.9
-7.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:HGF.Germany
Targacept, Inc., is a biopharmaceutical company engaged in the design, discovery and development of NNR Therapeutics, a new class of drugs for the treatment of diseases and disorders of the central nervous system. The company's NNR Therapeutics selectively target neuronal nicotinic receptors, or NNRs, which are found on nerve cells throughout the nervous system and serve as key regulators of nervous system activity. The company's most advanced product candidates are TC-5214, AZD3480 (TC-1734), TC-5619 and AZD1446. It has multiple clinical-stage product candidates and preclinical programs in areas where there are significant medical need and commercial potential, as well as proprietary drug discovery technologies. It also has a cognition-focused collaboration with AstraZeneca and a strategic alliance with GlaxoSmithKline. In July 2007, it entered into a product development and commercialization agreement with SmithKline Beecham Corporation, doing business as GlaxoSmithKline, and Glaxo Group Limited. The agreement sets forth the terms of an alliance designed to discover, develop and market product candidates that selectively target specified NNR subtypes in five therapeutic focus areas- pain, smoking cessation, addiction, obesity and Parkinson's disease. The company is conducting an ongoing Phase 2b clinical trial of TC-5214 as an augmentation treatment in subjects with major depressive disorder. The company might also conduct development of TC-5214 in one or more other indications. The company and AstraZeneca are conducting an ongoing exploratory Phase 2 trial of AZD3480 in adults with ADHD. TC-5619 is a novel small molecule that the company plans to develop for cognitive dysfunction in schizophrenia or potentially one or more other conditions characterized by cognitive impairment. TC-5619 modulates the activity of the a7 NNR. AZD1446 (TC-6683) is a novel small molecule that it discovered and advanced as part of the preclinical research collaboration that it is conducting with AstraZeneca. AZD1446 modulates the activity of the a4ß2 NNR and is in development for Alzheimer's disease, ADHD or one or more other conditions characterized by cognitive impairment.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide